Browsing Tag
Menarini Group
7 posts
RYALTRIS: Glenmark’s quiet blockbuster? A 45-market launch strategy explained
RYALTRIS is Glenmark’s global allergy brand launched in 45+ countries. Explore how it’s reshaping the firm’s branded strategy and global revenue mix.
Tempus AI and Stemline Therapeutics partner to advance AI-driven ESR1 mutation testing in metastatic breast cancer
Tempus AI, Inc. (NASDAQ: TEM) and Stemline Therapeutics, Inc., a wholly owned subsidiary of the Menarini Group, have…
Menarini’s EMERALD study of ORSERDU in breast cancer shows promising results
The Menarini Group and its subsidiary, Stemline Therapeutics, Inc., have made a significant stride in breast cancer treatment…
Menarini’s ORSERDU gets CHMP positive opinion in advanced breast cancer
The Menarini Group and its subsidiary, Stemline Therapeutics Inc., have received a favorable opinion from the European Medicines…
FDA approves Guardant360 CDx assay as companion diagnostic for Menarini’s ORSERDU for metastatic breast cancer
Guardant Health, an oncology company, has secured the approval of the US Food and Drug Administration (FDA) for…
Glenmark gets marketing approval for Ryaltris in 13 European countries
Glenmark Pharmaceuticals said that it has secured marketing approval for Ryaltris, a fixed-dose combination nasal spray, in 13…
Italy’s Menarini to acquire US biopharma company Stemline Therapeutics
Menarini acquisition of Stemline : Menarini Group, an Italian pharma and diagnostics company, has agreed to acquire US…